Keynote & Featured Presenters:
Immune Tolerance Induction: Novel Approaches for Novel Clinical Indications
Amy S. Rosenberg, M.D., Director, Division of Therapeutic Proteins, CDER/FDA
Relevance of Animal Models for Predicting the Immunogenicity of Therapeutic Proteins
Jack Ragheb, M.D., Ph.D., Principal Investigator, Immunology, Therapeutic Proteins, CDER/FDA
In vitro Prediction Technologies for Immunogenicity Assessment
Valerie Quarmby, Ph.D., Director and Principal Scientist, BioAnalytical Sciences, enentech, Inc.
Arrive early for part one of the Immungenicity Summit 2012: Immunogenicity Assessment and Clinical Relevance (October 10-11).
Register and view full details at: http://www.ImmunogenicitySummit.com
To inquire about sponsoring and/or exhibiting, contact Tim McLucas, 781-972-1342, email@example.com.
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at firstname.lastname@example.org.
About Cambridge Healthtech Institute (www.chicorporate.com)
CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.
Cambridge Healthtech Institute